The estimated Net Worth of Huda Y Zoghbi is at least $3.41 Million dollars as of 2 January 2024. Huda Zoghbi owns over 1,117 units of Regeneron Pharmaceuticals stock worth over $2,698,388 and over the last 8 years he sold REGN stock worth over $0. In addition, he makes $714,993 as Independent Director at Regeneron Pharmaceuticals.
Sign up
Huda Zoghbi REGN stock SEC Form 4 insiders trading
Huda has made over 7 trades of the Regeneron Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 1,117 units of REGN stock worth $437,775 on 2 January 2024.
The largest trade he's ever made was exercising 5,118 units of Regeneron Pharmaceuticals stock on 7 May 2020 worth over $2,005,847. On average, Huda trades about 960 units every 83 days since 2016. As of 2 January 2024 he still owns at least 2,364 units of Regeneron Pharmaceuticals stock.
You can see the complete history of Huda Zoghbi stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Huda Zoghbi biography
Dr. Huda Y. Zoghbi M.D. serves as Independent Director of the Company. She is currently a professor in the departments of Pediatrics, Molecular and Human Genetics, and Neurology and Neuroscience at Baylor College of Medicine, the director of the Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital, and an investigator of the Howard Hughes Medical Institute. She has been elected to the National Academy of Sciences, the Institute of Medicine, and the American Association for the Advancement of Science, and has been awarded numerous recognitions for her work, including the Pearl Meister Greengard Prize, the March of Dimes Prize in Developmental Biology, and the Vanderbilt Prize in Biomedical Science. Dr. Zoghbi earned her B.Sc. from the American University of Beirut, received her M.D. from Meharry Medical College in Nashville, Tennessee, and completed her pediatrics residency and a joint residency in neurology and pediatric neurology at Baylor College of Medicine, where she then pursued postdoctoral research training in molecular genetics. Dr. Zoghbi’s extensive research experience and her scientific and academic career and accomplishments led to the board’s decision to nominate Dr. Zoghbi for reelection to the board.
What is the salary of Huda Zoghbi?
As the Independent Director of Regeneron Pharmaceuticals, the total compensation of Huda Zoghbi at Regeneron Pharmaceuticals is $714,993. There are 19 executives at Regeneron Pharmaceuticals getting paid more, with P. Roy Vagelos having the highest compensation of $22,304,300.
How old is Huda Zoghbi?
Huda Zoghbi is 65, he's been the Independent Director of Regeneron Pharmaceuticals since 2016. There are 6 older and 18 younger executives at Regeneron Pharmaceuticals. The oldest executive at Regeneron Pharmaceuticals, Inc. is P. Roy Vagelos, 90, who is the Chairman of the Board, Director.
Insiders trading at Regeneron Pharmaceuticals
Over the last 22 years, insiders at Regeneron Pharmaceuticals have traded over $13,084,686,326 worth of Regeneron Pharmaceuticals stock and bought 8,562,481 units worth $2,539,854,760 . The most active insiders traders include Sanofi, Pharma Ag Novartis, and Leonard S Schleifer. On average, Regeneron Pharmaceuticals executives and independent directors trade stock every 8 days with the average trade being worth of $47,694,347. The most recent stock trade was executed by Marion Mc Court on 3 September 2024, trading 1,000 units of REGN stock currently worth $381,400.
What does Regeneron Pharmaceuticals do?
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.
What does Regeneron Pharmaceuticals's logo look like?
Complete history of Huda Zoghbi stock trades at Regeneron Pharmaceuticals
Regeneron Pharmaceuticals executives and stock owners
Regeneron Pharmaceuticals executives and other stock owners filed with the SEC include:
-
P. Roy Vagelos,
Chairman of the Board, Director -
Leonard Schleifer,
President, Chief Executive Officer, Director -
George Yancopoulos,
President, Chief Scientific Officer, Director -
Marion McCourt,
Senior Vice President - Commercial -
Andrew Murphy,
Executive Vice President - Research -
Neil Stahl,
Executive Vice President - Research and Development -
Robert Landry,
Chief Financial Officer, Executive Vice President - Finance -
Daniel Van Plew,
Executive Vice President, General Manager - Industrial Operations and Product Supply -
Dr. George D. Yancopoulos M.D., Ph.D.,
Scientific Founder, Pres, Chief Scientific Officer & Director -
Dr. Leonard S. Schleifer M.D., Ph.D.,
Founder, Pres, CEO & Director -
Dr. George D. Yancopoulos,
Scientific Founder, Pres, Chief Scientific Officer & Director -
Robert E. Landry Jr.,
Exec. VP of Fin. & CFO -
Daniel P. Van Plew,
Exec. VP and GM of Industrial Operations & Product Supply -
Joseph J. LaRosa,
Exec. VP, Gen. Counsel & Sec. -
Dr. Andrew J. Murphy,
Exec. VP of Research -
Arthur Ryan,
Independent Director -
George Sing,
Independent Director -
Christine Poon,
Independent Director -
Michael Brown,
Independent Director -
Huda Zoghbi,
Independent Director -
Joseph Goldstein,
Independent Director -
Bonnie Bassler,
Independent Director -
N. Anthony Coles,
Independent Director -
Marc Tessier-Lavigne,
Independent Director -
Christopher Fenimore,
Vice President, Controller -
Joseph LaRosa,
Executive Vice President, General Counsel, Secretary -
Justin Holko,
VP of Investor Relations -
Bob McCowan,
Sr. VP of IT & Chief Information Officer -
Gerald Underwood,
Sr. VP of Technical Operations -
Christopher R. Fenimore,
Sr. VP, Head of Accounting & Controller -
Patrice Gilooly,
Sr. VP of Quality Assurance & Operations -
Charles A Baker,
Director -
Michael S Aberman,
SVP Strategy Investor Relation -
Sanofi,
-
Robert J Terifay,
EVP Commercial -
Alfred G Gilman,
Director -
Robert Alexander Ingram,
Director -
Eric M Shooter,
Director -
Murray A Goldberg,
SVP Administration & Asst Secr -
Stuart Kolinski,
SVP General Counsel and Secret -
Amerique Du Nord S.N.C. San...,
-
Peter Dworkin,
VP Investor Relations & Commun -
Randall Rupp,
SVP, Manufuring Operations -
Pharma Ag Novartis,
10% owner -
Hans Peter Guler,
VP Clinical Programs -
William Roberts,
VP Reg Dev & Med Safety -
Peter Powchik,
SVP Clinical Development & Reg -
Douglas S Mc Corkle,
VP Controller and Asst Treasur -
Craig B. Thompson,
Director -
Kathryn Guarini,
Director -
David P Schenkein,
Director -
Jason Pitofsky,
VP Controller